Seeun Kong

Seeun Kong

Auto-generated profile, based on publicly available information

Seeun Kong

School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2026 in Journal of Liposome Research
Verified
Journal Article
Open access
PPPatrick Pan
Patrick Pan
YMYuhong Ma
Yuhong Ma
SKSeeun Kong
Seeun Kong
KAKamel Ahmed
Kamel Ahmed
Zimei WuZimei Wu
Zimei Wu
Oral liposome drug delivery system has gained attention due to their potential to improve patient compliance, enhance the bioavailability of encapsulated poorly soluble drugs, and protect drugs from gastrointestinal degradation. Liposomes structurally mimic the human cell membrane, and so are biocompatible and facilitate interactions with cell membranes. However, liposome drug delivery remains inherently challenging due to limitations such as physicochemical instability, limited permeability across GI barriers, and manufacturing scalability constraints. This review first summarizes the current innovative oral liposome products such as Meriva®, Lipicur, and silymarin liposomes. This is followed by a comprehensive overview of the biological barriers for liposome absorption. The report further reviews current understanding the mechanisms for liposomes to cross the GI track and enter the bloodstream, including cellular uptake, transepithelial transport, and lymphatic transport. Formulation strategies to improve absorption such as lipid composition, surface modification techniques such as PEGylation and chitosan are discussed. Understanding these properties is essential for enhancing transepithelial transport efficiency and designing effective oral liposome delivery systems. Finally, the recent development in manufacturing scalability is also covered. Owing to their favorable properties, oral liposome delivery systems remain an active area for innovations in expanding their applications. It is anticipated that demand for oral liposomal drug‑delivery systems will continue to grow, driven by the rising prevalence of chronic diseases that require long‑term therapeutic management.